Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Ahlskog JE, Uitti RJ.

Neurology. 2010 Apr 6;74(14):1143-8. doi: 10.1212/WNL.0b013e3181d7d8e2. Review.

2.

The delayed-start study in Parkinson disease: can't satisfy everyone.

Olanow CW, Rascol O.

Neurology. 2010 Apr 6;74(14):1149-50. doi: 10.1212/WNL.0b013e3181d7d94b. No abstract available.

PMID:
20368635
3.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
4.

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group.

Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402.

PMID:
19086083
6.

The role of rasagiline in the treatment of Parkinson's disease.

Leegwater-Kim J, Bortan E.

Clin Interv Aging. 2010 May 25;5:149-56. Review.

7.

What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?

Vanacore N.

Neuroepidemiology. 2010;35(3):213. doi: 10.1159/000313554. Epub 2010 Jul 27. No abstract available.

8.

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O.

Mov Disord. 2008 Nov 15;23(15):2194-201. doi: 10.1002/mds.22218.

PMID:
18932271
9.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
10.
11.

The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

Schwarzschild MA.

Neurology. 2010 Nov 23;75(21):1943-4; author reply 1944-5. doi: 10.1212/WNL.0b013e3181fac7f9. No abstract available.

PMID:
21098412
12.

[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].

van Laar T, Boon AJ, Bloem BR.

Ned Tijdschr Geneeskd. 2010;154:A2496. Dutch.

PMID:
20977789
13.

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Parkinson Study Group.

Arch Neurol. 2004 Apr;61(4):561-6.

PMID:
15096406
14.

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2. German.

PMID:
18833504
15.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators.

N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335. Erratum in: N Engl J Med. 2011 May 12;364(19):1882.

16.

Rasagiline in Parkinson's disease.

Schwarzschild MA.

N Engl J Med. 2010 Feb 18;362(7):658; author reply 658-9. No abstract available.

PMID:
20187261
17.

Clinical trials with rasagiline: evidence for short-term and long-term effects.

Siderowf A, Stern M.

Neurology. 2006 May 23;66(10 Suppl 4):S80-8.

PMID:
16717255
18.

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Clarke CE.

Mov Disord. 2008 Apr 30;23(6):784-9. doi: 10.1002/mds.21918.

PMID:
18175348
19.
20.

Reply to Drs. Olanow and Rascol.

Ahlskog JE, Uitti RJ.

Neurology. 2010 Apr 6;74(14):1151. doi: 10.1212/WNL.0b013e3181d7d93b. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk